A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.
The REPROCELL Blog
REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:
• How and where can we be research smarter?
• How can we reduce uncertainty?
• How can we better predict efficacy and safety?
• How can we reduce costs?
One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.
Pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), are a key component of the growing field of regenerative medicine. Use of culture conditions free of animal products (xeno-free) is essential for PSC projects that are destined for the clinic. NutriStem hPSC XF medium (01-0005) and iMatrix-511 recombinant human laminin-511 E8 fragments (NP8920911) form an ideal system for xeno-free, feeder culture of human PSCs.
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday, at https://www.dur.ac.uk/news/newsitem/?itemno=33385
Developed at the university by Professor Stefan Prsyborski, Alvetex was first commercialised by the spin-out company Reinnervate – based at NETPark in County Durham, UK. Reinnervate was acquired by REPROCELL Inc. (Japan) in 2014.
Stefan Przyborski is Professor of Cell Technology at Durham University’s Department of Biosciences and Chief Scientific Officer of REPROCELL Europe Ltd.